Adams Brian
Known title: Chief Legal OfficerCIK: 0001636994
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
RLAY Valuation Debate: Is the Pullback a Value Trap?. Recent analysis questions whether Relay Therapeutics is undervalued after its recent price drop or if the market has already priced in potential gains. One report suggests the stock is fully priced relative to its book value, while another asks if the current level offers a bargain. The stock is currently trading near a key support level, with analysts maintaining a higher average target price.
Transaction History
| KYMR | ▼ Sell | Open Market | 1,209 | $140K | 9/4/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 3,025 | $353K | 9/4/2026 | View on chart |
| KYMR | ▼ Sell | Open Market | 2,137 | $251K | 9/4/2026 | View on chart |
| KYMR | ▲ Buy | Grant | 4,125 | $0 | 3/2/2026 | View on chart |
| KYMR | ▲ Buy | Grant | 52,500 | $0 | 9/3/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 18,276 | $67K | 7/29/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,637 | $6K | 7/28/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 12,943 | $39K | 4/30/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,644 | $5K | 4/28/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 298 | $846 | 3/27/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 20,791 | $92K | 1/30/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 33,688 | $156K | 1/28/2025 | View on chart |
| RLAY | ▲ Buy | Grant | 139,141 | $0 | 1/28/2025 | View on chart |
| RLAY | ▼ Sell | Open Market | 299 | $1K | 12/27/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,632 | $10K | 10/28/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 295 | $2K | 9/27/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,638 | $14K | 7/29/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 295 | $2K | 6/27/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,623 | $10K | 4/29/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 348 | $3K | 3/27/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,929 | $19K | 1/29/2024 | View on chart |
| RLAY | ▲ Buy | Grant | 200,000 | $0 | 1/16/2024 | View on chart |
| RLAY | ▼ Sell | Open Market | 294 | $3K | 12/27/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,632 | $10K | 10/30/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 294 | $2K | 9/27/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 1,628 | $19K | 7/28/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 294 | $4K | 6/27/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 863 | $10K | 4/28/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 347 | $5K | 3/27/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 864 | $19K | 1/30/2023 | View on chart |
| RLAY | ▲ Buy | Grant | 85,425 | $0 | 1/17/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 9,994 | $200K | 1/12/2023 | View on chart |
| RLAY | ▼ Sell | Open Market | 295 | $4K | 12/27/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 728 | $16K | 10/28/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 294 | $7K | 9/27/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 734 | $16K | 7/28/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 300 | $6K | 6/27/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 708 | $18K | 4/28/2022 | View on chart |
| RLAY | ▼ Sell | Open Market | 333 | $10K | 3/29/2022 | View on chart |
| RLAY | ▲ Buy | Grant | 39,270 | $0 | 1/27/2022 | View on chart |
| RLAY | ▲ Buy | Grant | 658 | $17K | 12/31/2021 | View on chart |
| RLAY | ▼ Sell | Open Market | 295 | $10K | 12/27/2021 | View on chart |
| RLAY | ▼ Sell | Open Market | 6,500 | $230K | 11/15/2021 | View on chart |
| RLAY | ▲ Buy | Option Exercise | 6,500 | $27K | 11/15/2021 | View on chart |
| RLAY | ▼ Sell | Open Market | 293 | $11K | 9/27/2021 | View on chart |
| RLAY | ▲ Buy | Option Exercise | 6,500 | $27K | 9/13/2021 | View on chart |
| RLAY | ▼ Sell | Open Market | 6,500 | $228K | 9/13/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Raymond James initiates coverage on Kymera with Outperform rating
Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.
Raymond James initiates coverage on Kymera with Outperform rating. Raymond James has started covering Kymera Therapeutics, assigning an Outperform rating and a price target of $140. This new analyst note adds to the current consensus, which has an average target of $139.35 from 23 analysts. Recent discussions also question whether the company's pipeline is over-hyped or developing into a major therapeutic success.